All News
L17 @ #ACR23
New therapy on horizon for cutaneous LE (CLE)?
⭐️AFIMETORAN
➡️ TLR7/8 inhibitor
➡️1st-in-class orally bioavailable, potent
⭐️Phase Ib trial
➡️Criteria:
👉18-65 yo SLE vs biopsy proven CLE
👉CLE Dz Area & Severity Index (CLASI-A) at least 6
👉ANA… https://t.co/HPqw4d0AHl https://t.co/5u9aEvzdMb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR23 Late-Breaking Abstr#L19 IA steroid can help osteoarthritis knee pain but effect & duration are variable. Phase 3 RCT: improvement in ADP & WOMAC pain favouring TLC5999 (liposomal modification of DEX) vs PBO at all timepoints inc. after repeated injection @RheumNow #ACRBest https://t.co/xUhoFHPExr
Md Yuzaiful Md Yusof ( View Tweet)
Would intraarticular steroids for knee OA be better with a sustained release formulation?
ph3, TLL599 (liposomal delivery dexamethasone) vs normal dex vs placebo
some gains over normal dex
well tolerated
New options always welcome in OA!
@ProfDavidHunter #ACR23 L19 @RheumNow https://t.co/TUrhppHMiD
David Liew drdavidliew ( View Tweet)
L20 #ACR23 @RheumNow
Telitacept - Recomb Fusion targets BlyS, APRIL in RA w inadeq MTX response
ACR 20 60% v 27% PBO (p<0.001), ACR 50 21% v 6% PBO (p<0.001)
DAS28-ESR <3.2 15% v 5%, reduct -1.6 v -1.0
Better PROs, less jt damage prog at w24
Safety SAE 6.4 v 6.7%, no ifn signal https://t.co/PsA6AxUHVW
Eric Dein ( View Tweet)
Sustained relief for knee OA
TLC599 - liposomal formulation of dexamethasone sodium phosphate
Single injection provided relief for 24 weeks, repeat injection with benefit up to wk 52
@RheumNow #ACR23 Abs#L19
#ACRBest https://t.co/BNGb3nHw8C
Robert B Chao, MD ( View Tweet)
#ACR23 Late-Breaking Abstr#L20 Phase 3 RCT in China: Telitacicept (BAFF-APRIL-i) in MTX-IR #RA met ACR20 response vs PBO.
+ve: less radiographic damage
-ve: lower rate ACR50 (21%), homogenous population, no H2H active comparator
Unclear its place in current Mx @RheumNow https://t.co/SAc4B1aRD1
Md Yuzaiful Md Yusof ( View Tweet)
Telitacicept (BlyS/APRIL inhibitor) ph3 in RA
wholly in China, after SLE approval there (SLE trial now w global sites)
Efficacy okay, no better than other b/tsDMARDs
What's the hook here, in a crowded RA market incl biosimilars?
Safety does look good though
#ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A
David Liew drdavidliew ( View Tweet)
ICYMI
Interesting study by Dr LWGarcia et al:
👉IFN-a serum levels predicted failure to respond to tx 2 years after a flare in pts w/ LN
👉Pts w/⬆️BL IFN-a levels had greater risk of having 2 or more subsequent flares
#ACR23 ABST2297 @RheumNow @ZahiTouma https://t.co/WJZnNUPUbT
sheila ( View Tweet)
Interesting late breaker!
Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression
No difference in safety profile compared to placebo
@RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
Robert B Chao, MD ( View Tweet)
Telitacicept (BlyS/APRIL inhibitor) in MTX-IR RA. Phase 3 RCT. 479 patients. ACR20 60.0% vs 26.9%. ACR50 21.4% vs. 5.9%. Radiographic benefit also. Safety looks ok. Abstr#L20 #ACR23 #ACRbest @RheumNow https://t.co/qcinGeRX2d https://t.co/SIKKW7xhwV
Richard Conway ( View Tweet)
#ACRbest Peter Merkel as Distinguished Investigator said Data are good.
Need data to develop questions, understand #vasculitis Hx of #vasculitis - great minds & drugs -
now challenged by funding and comparators
Session 15W127 #ACR23 @RheumNow @ACRheum https://t.co/5leIeLWZ6O
Janet Pope ( View Tweet)
#ACR23 Abstr#2575 Do guidelines work? Data from UK cohort (N=290) re: utility of the International Guideline for IIM-assoc cancer screening detected 17 cases; most in high risk group & none in low risk. Need larger size, cases, screening timepoint & economic analysis @RheumNow https://t.co/G2bmmQbSox
Md Yuzaiful Md Yusof ( View Tweet)
Systematic review and meta-analysis of efficacy and and safety or therapies in Adult Onset Still's Disease and sJIA
IL-1i and IL-6i - highest evidence for treatment
Early (<3 months) intervention = higher rate of dz inactivity
@RheumNow #ACR23 Abs#2569 https://t.co/XzzwbLFpo7
Robert B Chao, MD ( View Tweet)
Tommasi et al. MTX (vs SSZ) lowers BP in RA in RCT. At 6 months, significant reduction in SBP (mean difference -4.0±10.8 mmHg, p=0.038), MAP (mean difference -4.3±17.9 mmHg, p=0.023). Abstr#2151 #ACR23 @RheumNow https://t.co/wAX3dCztxH https://t.co/mPG5TdeHTu
Richard Conway ( View Tweet)
#vasculitis clinical trials are accelerating. Need the right time - early studies have lessons learned re feasibility and design/endpoints #ACR23 @RheumNow @ACRheum Great lecture - P Merkel 15W127 great graphs of vasculitis developments https://t.co/YRdPiaflxY
Janet Pope ( View Tweet)
New MoA in RA 🚨
Dual inhibition BAFF/BLys Telalicept MTX IR pts Ph3 vs. PBO
ACR20 60 vs. 27%
ACR50 21 vs. 6%
DAS28<3.2 15 vs. 5%
Less Rx prog
Safety similar infection rates
@RheumNow #ACR23 ABSTL20 https://t.co/WHysLSKyo0
Aurelie Najm ( View Tweet)
Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT improved/stable in 76%. Dyspnoea stable/improved in 95%. Abstr#2174 #ACR23 @RheumNow https://t.co/j6SiEzSRif
Richard Conway ( View Tweet)
Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was withdrawn in 50 patients (21.5%) (ILD worsening 20, joint worsening 15, serious infections 7, others 8) Abstr#2165 #ACR23 @RheumNow https://t.co/SinE4GgFRE https://t.co/M1Nnce58OE
Richard Conway ( View Tweet)
Knee OA, to inject or not to inject: the great debate 📣
A thread👇🏼👇🏼👇🏼
Maglette Klotenburg argues in favor, with moderation
IA GC improves pain
Repetitive injections can be harmful
@RheumNow #ACR23 https://t.co/3p4UVLngpx
Aurelie Najm ( View Tweet)
#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz
Md Yuzaiful Md Yusof ( View Tweet)